Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Henagliflozein on Hepatic Fat Content in T2DM and NAFLD
NCT06449833Phase 4Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of henagliflozin in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), sponsored by Southern Medical University Zhujiang Hospital. Started Jun 2024; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06449833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449833.